109 related articles for article (PubMed ID: 4085312)
21. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
Burke PJ; Karp JE; Vaughan WP
J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
[TBL] [Abstract][Full Text] [Related]
22. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system.
Raymakers RA; Slocum HK; Minderman H; Malmberg M; Rustum YM
Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859
[TBL] [Abstract][Full Text] [Related]
23. Multivesicular liposomes containing cytarabine for slow-release Sc administration.
Kim S; Howell SB
Cancer Treat Rep; 1987 May; 71(5):447-50. PubMed ID: 3567968
[TBL] [Abstract][Full Text] [Related]
24. Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
Chabot GG; Momparler RL
Cancer Treat Rep; 1984 Dec; 68(12):1483-7. PubMed ID: 6210142
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210.
Kobayashi T; Tsukagoshi S; Sakurai Y
Gan; 1975 Dec; 66(6):719-20. PubMed ID: 1225724
[No Abstract] [Full Text] [Related]
26. Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy.
Kim S; Howell SB
Cancer Treat Rep; 1987; 71(7-8):705-11. PubMed ID: 3607782
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.
Kataoka T; Kobayashi T
Ann N Y Acad Sci; 1978; 308():387-94. PubMed ID: 279298
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
29. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
Rauko P; Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Schott H; Fritzer-Szekeres M; Novotny L; Szekeres T
Anticancer Res; 2003; 23(5A):3841-6. PubMed ID: 14666686
[TBL] [Abstract][Full Text] [Related]
30. Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size.
Hunt CA; Rustum YM; Mayhew E; Papahadjopoulos D
Drug Metab Dispos; 1979; 7(3):124-8. PubMed ID: 38080
[TBL] [Abstract][Full Text] [Related]
31. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine.
Schwendener RA; Schott H
Int J Cancer; 1992 May; 51(3):466-9. PubMed ID: 1592536
[TBL] [Abstract][Full Text] [Related]
32. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
Grem JL; Plowman J; Rubinstein L; Hawkins MJ; Harrison SD
Leuk Res; 1991; 15(4):229-36. PubMed ID: 2030604
[TBL] [Abstract][Full Text] [Related]
33. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.
Walsh CT; Craig RW; Agarwal RP
Cancer Res; 1980 Sep; 40(9):3286-92. PubMed ID: 7427943
[TBL] [Abstract][Full Text] [Related]
34. Effect and mode of action of N4-behenoyl-beta-D-arabinofuranosylcytosine.
Kataoka T; Sakurai Y
Recent Results Cancer Res; 1980; 70():147-51. PubMed ID: 7355245
[TBL] [Abstract][Full Text] [Related]
35. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats.
Allen TM; Everest JM
J Pharmacol Exp Ther; 1983 Aug; 226(2):539-44. PubMed ID: 6875864
[TBL] [Abstract][Full Text] [Related]
36. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
Matsushita T; Ryu EK; Hong CI; MacCoss M
Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939
[TBL] [Abstract][Full Text] [Related]
37. Cell kinetic studies of the cytostatic and cytocidal effect of 1-beta-D-arabinofuranosylcytosine on the L1210 ascites tumor.
Fietkau R; Friede H; Maurer-Schultze B
Cancer Res; 1984 Mar; 44(3):1105-13. PubMed ID: 6692397
[TBL] [Abstract][Full Text] [Related]
38. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
39. [Studies on the relationship between therapeutic schedule and antitumor effect of etoposide and cytosine arabinoside in murine L1210 leukemia].
Ooi K; Ohkubo T; Kawasaki H; Sakurai M
Yakugaku Zasshi; 1989 Nov; 109(11):865-8. PubMed ID: 2614669
[TBL] [Abstract][Full Text] [Related]
40. [Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy].
Schwendener RA; Schott H; Hartmann HR; Supersaxo A; Rubas W; Hengartner H
Onkologie; 1987 Aug; 10(4):232-9. PubMed ID: 2959889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]